Parkinson’s disease (PD) is a long-term neuro-degenerative disorder affecting motor neuron activities, characterized by tremor, rigidity, dementia, depression etc. The symptoms of this disease include rigidity, tremor, bradykinesia and postural instability. PD usually begins around age 60, but it can start earlier. It is more common in men than in women. The main aim of the Parkinson’s disease treatment is to provide control on signs and symptoms such as shakiness in hands, difficulty with walking, slowness of movement etc. Therapeutic approach for each person varies according to his or her symptoms. Presently, only symptomatic drug treatments are available in the market.
The global Parkinson’s Disease Drugs market is expected to grow at a rapid rate during the forecast period. The market has already witnessed approval of numerous drugs to treat Parkinson disease. In January 2018, Adamas Pharmaceuticals Inc. launched Gocovri (amantadine extended-release capsules) for the treatment of PD patients, who are consuming levodopa. Moreover, increasing aging population worldwide is expected to boost the growth of the PD Drugs market during the forecast period. However, many branded drugs are expected to lose their patent in the coming years. Hence, the arrival of the patented products is expected to witness intense competition against the future generic alternatives. Geographically, the market is segmented across four regions namely the Americas, EMEA region, APAC region, and ROW. Some of the key players in this market are Merck & Co. Inc., Boehringer Ingelheim, Impax Laboratories Inc., AbbVie Inc., Mylan NV, GlaxoSmithKline PLC., Somerset Pharmaceuticals Inc., Teva Pharmaceuticals, Pfizer, Novartis AG, and Allergan Plc.
Infoholic Research’s Global Parkinson’s Disease Drugs market report provides detailed information about various market trends and applications covering different segments and regions. The major trends, drivers, restraints, and opportunities in each segment are also covered. This study will help stakeholders to understand the current and future market outlook to focus/expand/invest in the Global Parkinson’s Disease Drugs market.
This report also provides the competitive landscape of the leading players in the Global Parkinson’s Disease Drugs market and this study will help the vendors to understand about their competitors’ landscape. The report can also be tailored as per the specific user requirement. The customization of the report is available based on countries, vendor profiles, enterprise, and vertical wise.
- Healthcare Category
- By Drug Types
- Dopamine Receptor Agonists
- Mao Inhibitors
- COMT Inhibitors
- By End Users
- By Regions
- North America
- Asia Pacific
- Rest of the World
Industry Outlook: Market Trends and Drivers, Restraints, and Opportunities